Newsroom

Sorted by: Latest

-

PennyMac Mortgage Investment Trust Reschedules Third Quarter 2026 Earnings Call to 6:30 PM ET on Thursday, October 29

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--PennyMac Mortgage Investment Trust (NYSE: PMT) will announce results for the quarter ended September 30, 2026, in a news release to be issued after the market close on Thursday, October 29, 2026. The conference call and live audio webcast is being rescheduled to 6:30 pm. Eastern Time from the originally scheduled 6:00 p.m. Eastern Time. The release, webcast, and accompanying materials will be available online at pmt.pennymac.com. A replay of the webcas...
-

Arrvel presenta una línea de lectores industriales de códigos de barras y terminales portátiles para empresas de todo el mundo

SHENZHEN, China--(BUSINESS WIRE)--A medida que las cadenas de suministro aceleran su transformación digital, las empresas de los sectores del comercio minorista, el almacenamiento, los servicios públicos y la gestión de activos necesitan herramientas cada vez más avanzadas para sus equipos de trabajo móviles. La necesidad de consultar inventarios en tiempo real, anticipar las necesidades logísticas y mantener conectadas las operaciones sobre el terreno impulsa la demanda de lectores de códigos...
-

Die neuartige In-vivo-Immuntherapie STC-1010 von Brenus Pharma hat sich als sicher erwiesen und aktiviert T-Zellen bei metastasiertem kolorektalem Karzinom im Stadium MSS in der Erstlinienbehandlung...

MADRID--(BUSINESS WIRE)--  Die neuartige In-vivo-Immuntherapie STC-1010 von Brenus Pharma hat sich als sicher erwiesen und aktiviert T-Zellen bei metastasiertem kolorektalem Karzinom im Stadium MSS in der Erstlinienbehandlung, wobei zwei vollständige Remissionen erzielt wurden Brenus Pharma, ein im klinischen Stadium tätiges Biotech-Unternehmen, gab erste Daten aus der Dosiseskalationsstudie der Phase Ia mit BreAK CRC-001 bekannt. Es wurden neun Patienten mit inoperablem Karzinom behandelt; 89...
-

Le STC-1010, une nouvelle immunothérapie in vivo développée par Brenus Pharma, s’est révélé sûr et a permis d’activer les lymphocytes T chez des patients atteints d’un cancer colorectal métastatique de statut MSS dans le cadre...

MADRID--(BUSINESS WIRE)--  Le STC-1010, une nouvelle immunothérapie in vivo développée par Brenus Pharma, s’est révélé sûr et a permis d’activer les lymphocytes T chez des patients atteints d’un cancer colorectal métastatique de statut MSS dans le cadre d’un traitement première intention, avec deux réponses complètes Brenus Pharma, une société de biotechnologie au stade clinique, a annoncé les premiers résultats de l’étude de phase Ia d’escalade de dose BreAK CRC-001. Neuf patients atteints d’u...
-

KBRA Assigns Preliminary Ratings to Foundation Finance Trust 2026-2

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to five classes of notes issued by Foundation Finance Trust 2026-2 (“FFIN 2026-2”), an asset-backed securitization collateralized by unsecured consumer loans primarily used for home improvements. FFIN 2026-2 will issue five classes of notes totaling $353.79 million, collateralized by $380.0 million receivables. FFIN 2026-2 has initial credit enhancement levels ranging from 46.90% for the Class A notes to 7.40% for the Class E notes. Cr...
-

استحواذ Stakk على ParaScript لإنشاء منصة عالمية للثقة الرقمية تركز على مكافحة الاحتيال

بولدر، كولورادو--(BUSINESS WIRE)--أعلنت اليوم شركة ParaScript، المتخصصة في مجال معالجة المستندات بالذكاء الاصطناعي، أنَّ شركة Stakk Limited (بورصة أستراليا: SKK) ("Stakk")، المدرجة للتداول العام في بورصة أستراليا (ASX)، قد أتمت بنجاح استحواذها على شركتي ParaScript, LLC وParaScript Management, Inc. ("ParaScript") بقيمة 63 مليون دولار أمريكي (88.7 مليون دولار أسترالي)، ما أدى إلى إنشاء منصة موسعة ومربحة للثقة الرقمية قائمة على الذكاء الاصطناعي.استحوذت Stakk على ParaScript بفضل تقنيتها الرائدة في م...
-

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details a...
-

AM Best Affirms Credit Ratings of The Hand-in-Hand Mutual Fire Insurance Company Limited and Hand-in-Hand Mutual Life Assurance Company Limited

MEXICO CITY--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating (FSR) of B++ (Good) and the Long-Term Issuer Credit Rating (Long-Term ICR) of “bbb+” (Good) of The Hand-in-Hand Mutual Fire Insurance Company Limited (HIHF) (Guyana). The outlook of the FSR is stable while the outlook of the Long-Term ICR is negative. Concurrently, AM Best has affirmed the FSR of B++ (Good) and the Long-Term ICR of “bbb” (Good) of Hand-in-Hand Mutual Life Assurance Company Limited (HIHL) (Guyana). T...
-

AM Best Afirma Calificaciones Crediticias de The Hand-in-Hand Mutual Fire Insurance Company Limited y Hand-in-Hand Mutual Life Assurance Company Limited

México, Ciudad de México--(BUSINESS WIRE)--AM Best ha afirmado la Calificación de Fortaleza Financiera (FSR, por sus siglas en inglés) de B++ (Buena) y la Calificación Crediticia de Emisor de Largo Plazo (ICR, por sus siglas en inglés) de “bbb+” (Buena) de Hand-in-Hand Mutual Fire Insurance Company Limited (HIHF) (Guyana). La perspectiva de la FSR es estable, mientras que la perspectiva de la ICR de Largo Plazo es negativa. Al mismo tiempo, AM Best ha afirmado la FSR de B++ (Buena) y la ICR de L...
-

PennyMac Financial Services, Inc. Reschedules Third Quarter 2026 Earnings Call to 5:30 PM ET on Thursday, October 29

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--PennyMac Financial Services, Inc. (NYSE: PFSI) will announce results for the quarter ended September 30, 2026, in a news release to be issued after the market close on Thursday, October 29, 2026. The conference call and live audio webcast is being rescheduled to 5:30 pm. Eastern Time from the originally scheduled 5:00 p.m. Eastern Time. The release, webcast, and accompanying materials will be available online at pfsi.pennymac.com. A replay of the webca...